NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in ...
Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab. Today we’ve published further draft guidance for public consultation that continues to not recommend ...
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over TA1044 26 February 2025 26 February 2025 Durvalumab with etoposide and either carboplatin or cisplatin for ...
A list of downloadable documents created during development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback